Monocyte CD64 expression as a novel biomarker for the disease activity of systemic lupus erythematosus

Lupus

Volumn 24, Issue 10, 2015, Pages 1076-1080

  Kikuchi Taura, A ^a   Yura, A ^a   Tsuji, S ^a   Ohshima, S ^a   Kitatoube, A ^a   Shimizu, T ^a   Nii, T ^a   Katayama, M ^b   Teshigawara, S ^a   Yoshimura, M ^a   Kudo Tanaka, E ^a   Harada, Y ^a   Matsushita, M ^a   Hashimoto, J ^a   Saeki, Y ^a  

^a MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

CD64; Hematologic changes; SLEDAI

Indexed keywords

BIOLOGICAL MARKER; CD64 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DNA ANTIBODY; ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; CYTOKINE; FC RECEPTOR;

ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FLOW CYTOMETRY; HUMAN; MONOCYTE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELAPSE; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; ADULT; BIOSYNTHESIS; BLOOD; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; PROCEDURES; SEVERITY OF ILLNESS INDEX;

ADULT; ANTIBODIES, ANTINUCLEAR; BIOMARKERS; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, IGG; SEVERITY OF ILLNESS INDEX;

EID: 84938793206     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315579093     Document Type: Article

References (16)

1. Luppi P, Rossiello MR, Faas S, Trucco M,. Genetic background and environment contribute synergistically to the onset of autoimmune diseases. J Mol Med 1995; 73: 381-393.
2. Cooper GS, Miller FW, Pandey JP,. The role of genetic factors in autoimmune disease: implications for environmental research. Environ Health Perspect 1999; 107 (Suppl 5): 693-700.
3. Mackay IR,. The etiopathogenesis of autoimmunity. Semin Liver Dis 2005; 25: 239-250.
4. Kamal A,. The efficacy of novel B cell biologics as the future of SLE treatment: a review. Autoimmun Rev 2014; 13: 1094-1101.
5. Bennett L, Palucka AK, Arce E,. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-723.
6. Maruyama J, Inokuma S,. Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol 2010; 37: 967-973.
7. Yang PT, Xiao WG, Zhao LJ,. Increase in the level of macrophage colony-stimulating factor in patients with systemic lupus erythematosus. Ann Rheum Dis 2008; 67: 429-430.
8. Baechler EC, Batliwalla FM, Karypis G,. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610-2615.
9. Feng X, Wu H, Grossman JM,. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2951-2962.
10. Malinger G, Lev D, Kidron D, Heredia F, Hershkovitz R, Lerman-Sagie T,. Differential diagnosis in fetuses with absent septum pellucidum. Ultrasound Obstet Gynecol 2005; 25: 42-49.
11. Zhuang H, Narain S, Sobel E,. Association of anti-nucleoprotein autoantibodies with upregulation of type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. Clin Immunol 2005; 117: 238-250.
12. Pascual V, Farkas L, Banchereau J,. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006; 18: 676-682.
13. Li Y, Lee PY, Kellner ES,. Monocyte surface expression of Fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus. Arthritis Res Ther 2010; 12: R90-R90.
14. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725-1725.
15. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH,. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
16. Banchereau J, Pascual V,. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006; 25: 383-392.